NetworkNewsBreaks – BriaCell Therapeutics Corp.’s (TSX-V: BCT) (OTCQB: BCTXF) Lead Product Candidate Highlighted in Frontiers in Immunology Publication
BriaCell Therapeutics (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, recently announced that a manuscript highlighting the company’s lead product candidate, Bria-IMT™, was published in Frontiers in Immunology. The manuscript describes the novel mechanism of action of Bria-IMT™ as well as encouraging clinical results observed in current and past clinical testing, including the notable reduction of tumor size in some patients with advanced metastatic breast cancer. The publication provides evidence for the unique immune-enhancing activity, which is believed to set the Bria-IMT™ approach apart from comparable therapies. “Our investigations into the mechanism of…







